Skin Autofluorescence, 5-Year Mortality, and Cardiovascular Events in Peripheral Arterial Disease

Schmidt, Ann Marie

doi:10.1161/atvbaha.114.303419

Cited by 7 publications

(5 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…35 AGE accumulation in tissue may further aggravate vascular leakiness and precipitate tissue damage. 36 Of additional note, enhanced tissue accumulation of AGE, at least in diabetic subjects, is dependent on the degree of albuminuria. 37 Elevated UAE and increased apoB fractions could, therefore, act in concert in promoting the development of atherosclerosis.…”

Section: Discussionmentioning

confidence: 99%

Apolipoprotein B Attenuates Albuminuria-Associated Cardiovascular Disease in Prevention of Renal and Vascular Endstage Disease (PREVEND) Participants

Corsetti

Gansevoort²,

Bakker³

et al. 2014

Journal of the American Society of Nephrology

View full text Add to dashboard Cite

Whether urinary albumin excretion relates to higher levels of atherogenic apolipoprotein B fractions in the nondiabetic population is uncertain. Such a relationship could explain, in part, the association of elevated urinary albumin excretion with cardiovascular disease risk. We assessed the relationship of urinary albumin excretion with apolipoprotein B fractions and determined whether the association of elevated urinary albumin excretion with incident cardiovascular events is modified by high apolipoprotein B fraction levels. We performed a prospective study on 8286 nondiabetic participants (580 participants with cardiovascular disease; 4.9 years median follow-up time) with fasting lipids, apolipoprotein B, and urinary albumin excretion determined at baseline. With adjustment for sex and age, micro-and macroalbuminuria were associated with increased apolipoprotein B fractions (non-HDL cholesterol, LDL cholesterol, triglycerides, and apolipoprotein B). All four apolipoprotein B fractions modified associations of urinary albumin excretion with incident cardiovascular disease (hazard ratios for interaction terms ranged from 0.89 to 0.94 with 95% confidence intervals ranging from 0.84 to 0.99 and P values ranging from 0.001 to 0.02 by Cox proportional hazards modeling). These interactions remained present after additional adjustment for conventional risk factors, eGFR, cardiovascular history, and lipid-lowering and antihypertensive drug treatments. Such modification was also observed when urinary albumin excretion was stratified into normo-, micro-, and macroalbuminuria. We conclude that there is an association between elevated urinary albumin excretion and apolipoprotein B fraction levels and a negative interaction between these variables in their associations with incident cardiovascular events. Elevated urinary albumin excretion may share common causal pathways with high apolipoprotein B fractions in the pathogenesis of cardiovascular disease.

show abstract

Section: Discussionmentioning

confidence: 99%

Apolipoprotein B Attenuates Albuminuria-Associated Cardiovascular Disease in Prevention of Renal and Vascular Endstage Disease (PREVEND) Participants

Corsetti

Gansevoort²,

Bakker³

et al. 2014

Journal of the American Society of Nephrology

View full text Add to dashboard Cite

show abstract

“…31-36 A series of reports demonstrating rise in circulating AGEs in people with diabetes 37-41 and chronic kidney disease 42,43 stimulated further interest in health implications of AGEs. This followed a plethora of empirical studies exhibiting an association between AGEs and a variety of conditions such as decline in memory with age, 44-46 pathophysiology of eye diseases, 47-49 polycystic ovary syndrome, 50-55 wound healing, 56-61 cardiovascular complications, 62-68 bone health, 69-71 periodontitis, 58,72 erectile dysfunction, 73-76 anemia in older community-dwelling women, 77 slow walking speed in older adults, 78 peripheral neuropathy, 79,80 peripheral artery disease, 81-85 obstructive sleep apnea, 86-89 islet β-cell dysfunction, 90…”

Section: Ages In Health and Diseasementioning

confidence: 99%

Advanced Glycation End Products and Risks for Chronic Diseases: Intervening Through Lifestyle Modification

Prasad

Davis

Imrhan

et al. 2017

American Journal of Lifestyle Medicine

View full text Add to dashboard Cite

Advanced glycation end products (AGEs) are a family of compounds of diverse chemical nature that are the products of nonenzymatic reactions between reducing sugars and proteins, lipids, or nucleic acids. AGEs bind to one or more of their multiple receptors (RAGE) found on a variety of cell types and elicit an array of biologic responses. In this review, we have summarized the data on the nature of AGEs and issues associated with their measurements, their receptors, and changes in their expression under different physiologic and disease states. Last, we have used this information to prescribe lifestyle choices to modulate AGE-RAGE cycle for better health.

show abstract

“…Az ismert perifériás érbeteg-ségben szenvedő páciensek (kizárási kritérium volt a sú-lyos veseelégtelenség vagy transzplantáció utáni állapot, a közelmúltban zajlott szívinfarktus vagy stroke) csoportjában az 5 éves mortalitás a tradicionális cardiovascularis rizikófaktoroktól függetlenül korrelált a SAF-mé-rés eredményével, hasonló összefüggés a nem fatális eseményekkel kapcsolatban is kimutatható volt [25]. A PAD követése során megfi gyelt mortalitás SAF-fal tör-ténő predikcióját egyéb felmérésben is bizonyították [26].…”

Section: Táblázatunclassified

A bőr-autofluoreszcencia és a konvencionális glykaemiás markerek kapcsolata diabeteses betegekben

et al. 2015

View full text Add to dashboard Cite

Relationship between skin autofl uorescence and conventional glycemic markers in patients with diabetesIntroduction: Skin autofl uorescence has a well-known signifi cance for screening diabetes and early diagnosis of vascular complications. It predicts cardiovascular events better than hemoglobin A1c, hence skin autofl uorescence is a marker of cumulative tissue glycemic load whereas hemoglobin A1c refl ects changes occurring in the previous 6-8 weeks. Aim: The aim of the authors was analyze the relationship between skin autofl uorescence and conventional glycemic markers in patients with diabetes. Method: Skin autofl uorescence measurements were performed in 2010 in 18 patients (10 men and 8 women with normal glomerular fi ltration rate; age, 61.4±13.8 years) with long term follow-up (2624 months, 476 laboratory results). Relationships between skin autofl uorescence values and fasting blood glucose, hemoglobin A1c levels and metabolic parameters obtained before and after skin autofl uorescence measurements were analysed using Spearman rank test. Results: The average skin autofl uorescence value was 2.88±0.65 arbitrary units. There were no signifi cant correlations between skin autofl uorescence and hemoglobin A1c levels obtained before (7.84±1.08%, p = 0.07) and after the skin autofl uorescence measurements (7.45±1.18%, p = 0.71). Skin autofl uorescence values also failed to show relationship with fasting blood glucose obtained before (p = 0.09) and after (p = 0.29) the skin autofl uorescence measurements. Conclusions: In patients with diabetes skin autofl uorescence may provide novel information about glycemic burden. Skin autofl uorescence values (which may presumably provide a more accurate estimation of the cardiovascular risk) do not correlate with hemoglobin A1c and fasting blood glucose Keywords: skin autofl uorescence, hemoglobin A1c, cardiovascular riskMácsai, E., Rakk, E., Miléder, M., Fulcz, Á. [Relationship between skin autofl uorescence and conventional glycemic markers in patients with diabetes]. Orv. Hetil., 2015, 156(33) EREDETI KÖZLEMÉNYRövidítések AGE = glikációs végtermékek; CABG = coronaria arteria bypass graft; CACS = coronaria arteria kalcifi kációs score; CGMS = (continuous glucose monitoring system) szövetiglü-kóz-szint monitorozása; CKD = krónikus veseelégtelenség; GFR = glomerulusfi ltrációs ráta; HbA 1c = hemoglobin-A-1c; IGT = csökkent glükóztolerancia; PAD = perifériás artériás betegség; RAGE = (receptor for AGE) glikációs végtermékek receptora; SAF = bőr-autofl uoreszcencia; T1DM = diabetes mellitus 1-es típus; T2DM = diabetes mellitus 2-es típus

show abstract

Skin Autofluorescence, 5-Year Mortality, and Cardiovascular Events in Peripheral Arterial Disease

Cited by 7 publications

References 27 publications

Apolipoprotein B Attenuates Albuminuria-Associated Cardiovascular Disease in Prevention of Renal and Vascular Endstage Disease (PREVEND) Participants

Apolipoprotein B Attenuates Albuminuria-Associated Cardiovascular Disease in Prevention of Renal and Vascular Endstage Disease (PREVEND) Participants

Advanced Glycation End Products and Risks for Chronic Diseases: Intervening Through Lifestyle Modification

A bőr-autofluoreszcencia és a konvencionális glykaemiás markerek kapcsolata diabeteses betegekben

Contact Info

Product

Resources

About